Plandaí Biotechnology, Inc. PLPL OTC

Plandaí Biotechnology, Inc. (PLPL) generated $15.64M in operating cash flow for fiscal year 2023. After capital expenditures of $3.00, free cash flow was $15.64M.

Cash conversion ratio was 0.98x, suggesting some earnings are non-cash.

The company returned $3.93M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 0.98x suggests some earnings are non-cash items

Overall SharesGrow Score: 21/100 with 0/7 criteria passed.